ArticleJournal of the National Cancer Institute2010
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
Article in Journal of the National Cancer Institute, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01121640 (A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women), which is not on this map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 199 citations in OpenAlex.
- Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.The Cochrane database of systematic reviews · 2022Pooled it
- Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.BioMed research international · 2015Trial
- Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Trial
- Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- Designing early detection programs for ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2011Trial
- Identification of macrophage-enriched genes in ovarian cancer by single-cell RNA sequencing and establishment of a prognosis model.Scientific reports · 2026Article
- Predictive ability of novel glycovariant biomarkers of CA125 and CA15-3 up to three years prior to ovarian cancer diagnosis: a population-based case-control study.Journal of ovarian research · 2026Article
- Impaired natural killer cell maturation in lung adenocarcinoma driven byTranslational lung cancer research · 2025Article
- Bayesian and deep-learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers.Cancer medicine · 2024Article
- Use of Sensor Array Analysis to Detect Ovarian Cancer through Breath, Urine, and Blood: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2024Article
- Review
- An autophagy-related diagnostic biomarker for uterine fibroids: FOS.Frontiers in medicine · 2023Article
- Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022Review
- Prediction of occult tumor progression via platelet RNAs in a mouse melanoma model: a potential new platform for early detection of cancer.Journal of translational medicine · 2022Article
- PLP1 may serve as a potential diagnostic biomarker of uterine fibroids.Frontiers in genetics · 2022Article
- Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?EBioMedicine · 2021Article
- Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2.Abdominal radiology (New York) · 2021Article
- Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Empirical evaluation of sub-cohort sampling designs for risk prediction modeling.Journal of applied statistics · 2021Article
- A Refinement of Clinical Tumor Marker Monitoring: Why Not Use an Inverse Value of Doubling Time?Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundCA125, human epididymis protein 4 (HE4), mesothelin, B7-H4, decoy receptor 3 (DcR3), and spondin-2 have been identified as potential ovarian cancer biomarkers. Except for CA125, their behavior in the prediagnostic period has not been evaluated.
methodsImmunoassays were used to determine concentrations of CA125, HE4, mesothelin, B7-H4, DcR3, and spondin-2 proteins in prediagnostic serum specimens (1-11 samples per participant) that were contributed 0-18 years before ovarian cancer diagnosis from 34 patients with ovarian cancer (15 with advanced-stage serous carcinoma) and during a comparable time interval before the reference date from 70 matched control subjects who were participating in the Carotene and Retinol Efficacy Trial. Lowess curves were fit to biomarker levels in cancer patients and control subjects separately to summarize mean levels over time. Receiver operating characteristic curves were plotted, and area-under-the curve (AUC) statistics were computed to summarize the discrimination ability of these biomarkers by time before diagnosis.
resultsSmoothed mean concentrations of CA125, HE4, and mesothelin (but not of B7-H4, DcR3, and spondin-2) began to increase (visually) in cancer patients relative to control subjects approximately 3 years before diagnosis but reached detectable elevations only within the final year before diagnosis. In descriptive receiver operating characteristic analyses, the discriminatory power of these biomarkers was limited (AUC statistics range = 0.56-0.75) but showed increasing accuracy with time approaching diagnosis (eg, AUC statistics for CA125 were 0.57, 0.68, and 0.74 for > or = 4, 2-4, and <2 years before diagnosis, respectively).
conclusionSerum concentrations of CA125, HE4, and mesothelin may provide evidence of ovarian cancer 3 years before clinical diagnosis, but the likely lead time associated with these markers appears to be less than 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.